Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: The importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases

Journal of Cheminformatics

Volumn 5, Issue 1, 2013, Pages

  Paricharak, Shardul ^a   Klenka, Tom ^b   Augustin, Martin ^b   Patel, Umesh A ^c   Bender, Andreas ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Millipore   (United Kingdom)

^c The EMD Millipore Corporation   (United States)

Author keywords

Chemogenomics; Kinase inhibitor; Phylogenetics; Polypharmacology; Selectivity

Indexed keywords

EID: 84977556624     PISSN: None     EISSN: 17582946     Source Type: Journal    
DOI: 10.1186/1758-2946-5-49     Document Type: Article

References (61)

1. Liao JJ-L: Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem. 2007, 50: 409-424. 10.1021/jm0608107.
2. Hanks SK, Hunter T: The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995, 9: 576-596.
3. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias J-M, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005, 23: 329-336. 10.1038/nbt1068.
4. Zhang Z: Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol. 2002, 42: 209-234. 10.1146/annurev.pharmtox.42.083001.144616.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science (80-.). 2002, 298: 1912-1934. 10.1126/science.1075762.
6. Hanks SK: Genomic analysis of the eukaryotic protein kinase superfamily: a perspective. Genome Biol. 2003, 4: 111-10.1186/gb-2003-4-5-111.
7. Weinmann H, Metternich R: Drug discovery process for kinase inhibitors. Chembiochem. 2005, 6: 455-459. 10.1002/cbic.200500034.
8. Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R: Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res. 2003, 9: 1972-1979.
9. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM: Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003, 98: 437-457. 10.1002/cncr.11520.
10. Koskela H, Koskenvesa P, Mustjoki S, Porkka K: Current therapy of chronic myeloid leukemia. Duodecim. 2012, 128: 579-588.
11. Arce-Lara C, Shah MH, Jimenez RE, Patel VR, Benson DM, Clinton SK, Monk JP: Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach. Urology. 2007, 69: 1209.e5-1209.e7.
12. Bongers M, Coupé VMh, Jansma E, Smit E, Uyl-de-Groot CA: Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics. 2012, 30: 17-34. 10.2165/11595000-000000000-00000.
13. Rexer B, Arteaga C: Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012, 17: 1-16. 10.1615/CritRevOncog.v17.i1.20.
14. Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ: Navigating the kinome. Nat Chem Biol. 2011, 7: 200-202. 10.1038/nchembio.530.
15. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL: Global mapping of pharmacological space. Nat Biotechnol. 2006, 24: 805-815. 10.1038/nbt1228.
16. Krystal GW: Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leuk Res. 2004, 28 (Suppl 1): S53-S59.
17. Donner A: Stem cells: Imatinib gets beta. Nat Chem Biol. 2012, 8: 502-
18. Nagano T, Kotani Y, Kobayashi K, Hatakeyama Y, Hori S, Kasai D, Funada Y, Nishimura H, Kondoh T, Nishimura Y: Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status. Intern Med. 2011, 50: 3019-3022. 10.2169/internalmedicine.50.5903.
19. Tsang RY, Finn RS: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer. 2012, 106: 6-13. 10.1038/bjc.2011.516.
20. Knight ZA, Lin H, Shokat KM: Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010, 10: 130-137. 10.1038/nrc2787.
21. Bamborough P, Drewry D, Harper G, Smith GK, Schneider K: Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem. 2008, 51: 7898-7914. 10.1021/jm8011036.
22. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H: Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta. 2004, 1697: 243-257. 10.1016/j.bbapap.2003.11.028.
23. Vieth M, Sutherland JJ, Robertson DH, Campbell RM: Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today. 2005, 10: 839-846. 10.1016/S1359-6446(05)03477-X.
24. Van der Horst E, Peironcely JE, Van Westen GJP, Van den Hoven OO, Galloway WRJD, Spring DR, Wegner JK, Van Vlijmen HWT, IJzerman AP, Overington JP, Bender A: Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space. Curr Top Med Chem. 2011, 11: 1964-1977. 10.2174/156802611796391230.
25. Van der Horst E, Peironcely JE, IJzerman AP, Beukers MW, Lane JR, Van Vlijmen HWT, Emmerich MTM, Okuno Y, Bender A: A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. BMC Bioinforma. 2010, 11: 316-10.1186/1471-2105-11-316.
26. Bender A, Young DW, Jenkins JL, Serrano M, Mikhailov D, Clemens PA, Davies JW: Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb Chem High Throughput Screen. 2007, 10: 719-731. 10.2174/138620707782507313.
27. Lounkine E, Kutchukian P, Petrone P, Davies JW, Glick M: Chemotography for multi-target SAR analysis in the context of biological pathways. Bioorg Med Chem. 2012, 20: 5416-5427. 10.1016/j.bmc.2012.02.034.
28. Cheng F, Zhou Y, Li J, Li W, Liu G, Tang Y: Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. Mol Biosyst. 2012, 8: 2373-2384. 10.1039/c2mb25110h.
29. Sos ML, Rode HB, Heynck S, Martin P, Fischer F, Klüter S, Pawar VG, Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M, Simard JR, Getlik M, Yuza Y, Chen TH, Greulich H, Thomas RK, Rauh D: Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010, 70: 868-874. 10.1158/0008-5472.CAN-09-3106.
30. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008, 26: 127-132. 10.1038/nbt1358.
31. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen M-L, Wityak J, Borzilleri RM: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004, 47: 6658-6661. 10.1021/jm049486a.
32. Kuhn D, Weskamp N, Hüllermeier E, Klebe G: Functional classification of protein kinase binding sites using Cavbase. ChemMedChem. 2007, 2: 1432-1447. 10.1002/cmdc.200700075.
33. Milletti F, Vulpetti A: Predicting polypharmacology by binding site similarity: from kinases to the protein universe. J Chem Inf Model. 2010, 50: 1418-1431. 10.1021/ci1001263.
34. Martin E, Mukherjee P: Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome. J Chem Inf Model. 2012, 52: 156-170. 10.1021/ci200314j.
35. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP: Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011, 29: 1046-1051. 10.1038/nbt.1990.
36. Inhibitor Libraries and Pathway Panels: http://www.emdmillipore.com/life-science-research/inhibitor-libraries-and-pathway-panels/c-bKSb.s1O9nQAAAEitTV5hDHD?/p-uuid (accessed Oct 16, 2012)
37. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J. 2013, 451: 313-328. 10.1042/BJ20121418.
38. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol. 2011, 29: 1039-1045. 10.1038/nbt.2017.
39. Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, Scheiber J, Jenkins JL, Deng Z, Hill W, Popov M, Jacoby E, Glick M: Which aspects of HTS are emperically correlated with downstream success?. Curr Opin Drug Discov Devel. 2008, 11: 327-337.
40. Zuccotto F, Ardini E, Casale E, Angiolini M: Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem. 2010, 53: 2681-2694. 10.1021/jm901443h.
41. Kalliokoski T, Vulpetti A: Large-scale evaluation of CavBase for analyzing the polypharmacology of Kinase inhibitors. Mol Inf. 2011, 30: 923-925. 10.1002/minf.201100112.
42. Levitzki A: Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 2013, 53: 161-185. 10.1146/annurev-pharmtox-011112-140341.
43. Wawer M, Peltason L, Weskamp N, Teckentrup A, Bajorath J: Structure-activity relationship anatomy by network-like similarity graphs and local structure-activity relationship indices. J Med Chem. 2008, 51: 6075-6084. 10.1021/jm800867g.
44. Norman RA, Toader D, Ferguson AD: Structural approaches to obtain kinase selectivity. Trends Pharmacol Sci. 2012, 33: 273-278. 10.1016/j.tips.2012.03.005.
45. Merck Millipore KinaseProfiler Service Assay Protocols: http://www.millipore.com/techpublications/tech1/pf3036 (accessed Oct 27, 2012)
46. Chemical Computing Group Inc: Molecular Operating Environment (MOE). http://www.chemcomp.com/software.htm (accessed Oct 27, 2012)
47. Rogers D, Hahn M: Extended-connectivity fingerprints. J Chem Inf Model. 2010, 50: 742-754. 10.1021/ci100050t.
48. Bender A, Jenkins JL, Scheiber J, Sukuru SCK, Glick M, Davies JW: How similar are similarity searching methods? A principal component analysis of molecular descriptor space. J Chem Inf Model. 2009, 49: 108-119. 10.1021/ci800249s.
49. Bender A, Mussa HY, Glen RC: Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): evaluation of performance. J Chem Inf Model. 2004, 44: 1708-1718. 10.1021/ci0498719.
50. Hinselmann G, Rosenbaum L, Jahn A, Fechner N, Zell A: jCompoundMapper: an open source Java library and command-line tool for chemical fingerprints. J Cheminform. 2011, 3: 3-10.1186/1758-2946-3-3.
51. Sutherland JJ, Higgs RE, Watson I, Vieth M: Chemical fragments as foundations for understanding target space and activity prediction. J Med Chem. 2008, 51: 2689-2700. 10.1021/jm701399f.
52. Alix B, Boubacar DA, Vladimir M: T-REX: a web server for inferring, validating and visualizing phylogenetic trees and networks. Nucleic Acids Res. 2012, 40: W573-W579. 10.1093/nar/gks485.
53. The Human Kinome: http://kinase.com/human/kinome/ (accessed Oct 27, 2012)
54. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011, 28: 2731-2739. 10.1093/molbev/msr121.
55. Felsenstein J: PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics. 1989, 5: 164-166.
56. Letunic I, Bork P: Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics. 2007, 23: 127-128. 10.1093/bioinformatics/btl529.
57. Zmasek CM: Archaeopteryx: Visualization, Analysis, and Editing of Phylogenetic Trees. http://www.phylosoft.org/archaeopteryx/ (accessed 25 July, 2012)
58. Letunic I, Bork P: Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. Nucleic Acids Res. 2011, 39: W475-W478. 10.1093/nar/gkr201.
59. Merck Millipore DART: http://www.millipore.com/life-sciences/flx4/dart (accessed Oct 27, 2012)
60. Dessau RB, Pipper CB: "R"-project for statistical computing. Ugeskr Laeger. 2008, 170: 328-330.
61. Orange Canvas: http://orange.biolab.si/ (accessed Oct 27, 2012)